AXSM

Q3 '20

Last Updated:

Axsome Therapeutics Inc.

Our Mission: For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines

Cash

$202.4M

Burn Rate (Quarterly)

$22.9M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

AXS-05 (NMDA receptor antagonist)

Major Depressive Disorder

NDA Filing

January 2021

AXS-07

Migraine

NDA Filing

Q1 2021

AXS-14 (esreboxetine)

Fibromyalgia

Meeting with FDA

Q1 2021

AXS-05

Alzheimer's Disease Agitation

Phase 3 To Be Initiated

Q4 2020

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon